Listed by the USPTO as PAPCIAK, SHARON M
Tech Center 1600 • Art Units: 1651 1657
This examiner grants 50% of resolved cases
Sharon M. Papciak is assigned to Tech Center 1600 and art unit 1651. Her record contains 521 resolved cases, with a 49.5% allowance rate and a median of 1156 days to allowance. The figures indicate a docket where applicants may need to address allowance uncertainty while maintaining prosecution strategy over an extended timeline.
The interview lift is 22.5%, showing a meaningful recorded association between interviews and allowance outcomes. The leading companies are Novozymes A/S and Algenuity Holdings Ltd. No leading firms are listed. Practitioners may give interviews a defined role in prosecution planning, supported by precise claim amendments and a well-developed technical record.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18029590 | New Granules for Animal Feed | Final Rejection | Novozymes A/S |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy49.5% of resolved applications examined by Sharon M Papciak were allowed (521 resolved cases), compared with 31.6% across Art Unit 1651 over the last five years.
This examiner's interview lift is +22.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Sharon M Papciak took 1,156 days on average from filing to allowance.
Sharon M Papciak examines applications in Art Unit 1651 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
